Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in
- PDF / 3,501,066 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 45 Downloads / 160 Views
CLINICAL STUDY
Multiparametric MR‑PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment‑naïve diffuse gliomas Hiroyuki Tatekawa1,2 · Akifumi Hagiwara1,2 · Hiroyuki Uetani2 · Jingwen Yao1,2,3 · Talia C. Oughourlian1,2,4 · Shadfar Bahri5 · Chencai Wang1,2 · Catalina Raymond1,2 · Albert Lai6,7 · Timothy F. Cloughesy6,7 · Phioanh L. Nghiemphu6,7 · Linda M. Liau6,8 · Whitney B. Pope2 · Noriko Salamon2 · Benjamin M. Ellingson1,2,3,4,6 Received: 29 July 2020 / Accepted: 31 August 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose To assess whether hypermetabolically-defined regions of interest (ROIs) on 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) positron emission tomography (PET) could be used to evaluate physiological features and whether there are measurable differences between molecular subtypes and tumor grades. Methods Sixty-eight treatment-naïve glioma patients who underwent FDOPA PET and magnetic resonance imaging (MRI) were retrospectively included. Fluid-attenuated inversion recovery hyperintense regions (FLAIRROI) were segmented. FDOPA hypermetabolic regions (FDOPAROI, tumor-to-striatum ratios > 1) within FLAIRROI were extracted. Normalized maximum standardized uptake value ( nSUVmax), volume of each ROI, and median relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) within FLAIRROI or FDOPAROI were calculated. Imaging metrics were compared using Students t or Mann–Whitney U tests. Area under the curve (AUC) of receiver-operating characteristic curves were used to determine whether imaging metrics within FLAIRROI or FDOPAROI can discriminate different molecular statuses or grades. Results Using either F LAIRROI or FDOPAROI, the n SUVmax and rCBV were significantly higher and the ADC was lower in isocitrate dehydrogenase (IDH) wild-type than mutant gliomas, and in higher-grade gliomas (HGGs) than lower-grade gliomas (LGGs). The FDOPAROI volume was significantly higher in 1p19q codeleted than non-codeleted gliomas, and in HGGs than LGGs. Although not significant, imaging metrics extracted by FDOPAROI discriminated molecular status and tumor grade more accurately than those extracted by FLAIRROI (AUC of IDH status, 0.87 vs. 0.82; 1p19q status, 0.78 vs. 0.73; grade, 0.87 vs. 0.76). Conclusion FDOPA hypermetabolic ROI may extract useful imaging features of gliomas, which can illuminate biological differences between different molecular status or tumor grades. Keywords FDOPA PET · Hypermetabolic ROI · Glioma · MRI
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11060-020-03613-6) contains supplementary material, which is available to authorized users. * Benjamin M. Ellingson [email protected] Extended author information available on the last page of the article
Recently, various advanced magnetic resonance imaging (MRI) sequences, including perfusion imaging, d
Data Loading...
